E-mail: K.Ho@garvan.org.au
Received 2007-12-12 Accepted 2007-12-19
DOI: 10.1111/j.1745-7262.2008.00395.x
1 Introduction
Despite being banned by the World Anti-Doping Agency (WADA), there is widespread abuse of growth hormone
(GH), which is often used together with other banned substances such as anabolic steroids. A robust test is required
to enforce the ban on GH; however, developing a test for a naturally-occurring polypeptide such as GH has been a
challenge. This review examines the two main current approaches for GH detection based on isoforms of GH and on
serum GH-responsive markers, describing the basis of each approach and its current status as a doping test. Future
directions in the application of these tests, together with novel approaches being undertaken are also considered.
2 Abuse of GH in sport
There is anecdotal evidence that GH is widely abused, as indicated by the number of website hits for GH supply
and by customs and police drugs seizures. The abuse of GH by athletes is probably a result of the immense pressure
to perform in sport, which is reflected in a frequently-cited survey in which 98% of athletes said they would take a
performance-enhancing substance that would guarantee an Olympic medal if they could not be caught [1]. Amazingly,
when asked if they would take the drug if there were a guarantee that they would not get caught and would win every
competition for the next 5 years, even if they then died
from its adverse effects, 50% also replied yes [1].
The abuse of GH may start at young ages. An early
survey of 10th grade boys in the USA indicated that 5%
had taken GH, with more than half using GH in conjunction with steroids [2]. Large surveys of US
secondary school students have since reported an increase
in the use of anabolic steroids in the late 1990s,
followed by a subsequent decline in prevalence of their
use [3]. Although the most recent National Collegiate
Athletic Association survey of college athletes in the
USA also indicates decreased use of anabolic steroids,
1.2% of the athletes reported using GH in the past
12 months [4]. Doses used by athletes are estimated
to range from 3 mg to 8 mg daily for 3_4 days per
week, often used in combination with other doping agents [5], resulting in average daily doses of 1_2 mg
GH, approximately 2_3 times the daily endogenous
pituitary secretion. "Polypharmacy" is widely practiced
and GH is reportedly used in particular with anabolic
steroids. A web-based survey reports the use of GH
(1_10 mg/day) and insulin together with anabolic
androgenic steroids (AAS) by 25% of AAS users [6]. The
AAS abusers typically "stack" with several AAS, with
60% of those surveyed using > 1 000 mg AAS/week.
A typical "complex cycle" reported consisted of high
doses for a long period: 3 500 mg AAS/week together
with 2 mg/day GH for 20 weeks [6]. Another web-based
survey of weightlifters and body builders reports use
of GH together with anabolic steroids by 5% of steroid
users [7].
To date, there has been a lack of evidence that GH
actually improves performance in athletes. Although
beneficial effects have been demonstrated in adults with GH
deficiency, in healthy young adults the balance of
evidence has been against any beneficial effect of GH on
strength and fitness [8_10]. Although GH has been
demonstrated to induce a measurable protein anabolic effect
in athletes [11], there has been no evidence from
double-blind placebo-controlled studies to indicate that GH
enhances muscle strength or performance in trained adult
athletes [12, 13].
There are, however, adverse effects of long-term
abuse of GH, broadly related to its known physiological
effects on metabolism and growth. These include
insulin resistance and increased risk of diabetes in
susceptible individuals, fluid retention resulting in oedema,
carpal tunnel syndrome or athralgia, and possibly
cardiomyopathy and increased risk of malignancy [14]. The
severity of these adverse effects might be worsened by
concurrent abuse of anabolic steroids, which could have
synergistic effects with GH, such as effects on fluid
retention [15] and effects in power athletes on the
myocardium [16, 17]. Because of the health risks that it
poses to athletes and its potential to enhance sports
performance, in addition to violating the spirit of sports,
GH is listed in the 2008 Prohibited List
(http://www.wada-ama.org/rtecontent/document/2008_List_En.pdf)
as prohibited by the World Anti-Doping Code at all times,
both in-competition and out-of-competition.
3 Challenges in developing a robust test
Developing a robust test for detecting GH abuse has
been a challenge. Most current doping tests use urine,
which until recently was the only body fluid available for
sports doping testing. Urine is easily obtained, and in
relatively large volumes compared to blood samples.
However, the concentration of GH in urine is very low,
at levels approximately 0.1%_1% of that found in blood.
In addition, it is variable, with much of the variability not
accounted for by the variations in serum GH [18, 19].
Although urinary GH concentration increases after
administration of exogenous GH, increases can also occur
following exercise [20]. For these reasons, urinary
testing for GH is unlikely to be successful.
Detection of a naturally-occurring polypeptide, such
as GH, is challenging because recombinant human 22 kDa
(22K) GH available commercially and used in doping has
the identical amino acid sequence to the 22K GH isoform
secreted endogenously by the pituitary gland and is
indistinguishable from it using current analytical methods.
Differences in glycosylation patterns have been used to
distinguish between exogenous recombinant hormone and
endogenously secreted hormone as the basis for a test
for erythropoietin [21]; however, this is not currently
feasible for GH, which does not have N-linked
glycosylation sites in the 1_191 sequence.
GH has a short half-life of 15_20 min in the
circulation and exogenous GH administered by injection
disappears rapidly from the circulation [22]. The circulating
concentrations of GH also vary widely, because GH is
secreted from the pituitary in a pulsatile manner and is
regulated by several factors, including sleep, exercise and
stress [23]. Exercise is a major stimulus to GH secretion:
plasma concentrations can increase up to 10-fold, with
the increases in GH dependent on the duration, intensity
and nature of the exercise [10]. Therefore, because of
the widely fluctuating physiological GH concentrations,
in particular in response to exercise, increases in
circulating GH are not specific for exogenous GH
administration and direct measurement of total circulating GH
cannot be used for a robust GH test.
4 Physiological basis for GH tests
The first approach to testing for GH doping is based
on the physiology of GH secretion. GH is secreted by
the pituitary and circulates as a number of different
isoforms [24]. GH expressed in the pituitary from the
GH-N gene is subject to alternate splicing into different
isoforms, post-translational modifications, proteolysis,
formation of oligomers and binding to GH-binding
proteins [24, 25]. The 191 amino acid 22K GH isoform is
the most abundant form of GH, comprising approximately 50% of circulating GH in the monomeric form.
The 20 kDa (20K) GH isoform lacks 15 amino acids
(corresponding to residues 32_46 of the 1_191 sequence) and results from alternative splicing of the
GH-N gene. 20K GH is the second most abundant monomer in the circulation (approximately 10%_15%)
and has a longer half-life in the circulation compared to
22K GH [26]. Other 17.08 kDa and 17.84 kDa splice
variants have been identified by proteomic analysis in
human pituitary at low abundance (< 4% total pituitary
GH) [27]. In addition to splice variants, other isoforms
of GH differ in post-translational modifications,
including acetylation, deamidation and phosphorylation [27].
Proteolytic fragments of GH have also been described,
including 5 kDa and 17 kDa human GH [28]. The
different isoforms of GH also form oligomers (dimers,
trimers, tetramers, pentamers and possibly higher oligomers) in homopolymeric and heteropolymeric
combinations, which comprise approximately 30% of circulating GH. Links between the components of the
oligomers can be disulphide or other covalent links, or
non-covalent. Furthermore, in the circulation, complexes
form between 22K and 20K GH and GH binding proteins [24].
Negative feedback regulation by circulating GH and
IGF-I inhibits the secretion of pituitary GH [29]; therefore,
administration of GH results in reduced concentrations
of other endogenous GH isoforms secreted by the
pituitary [26]. Injection of exogenous recombinant 22K GH
results in increased circulating concentrations of 22K GH
and an increase, therefore, in its relative abundance
because of the decrease in other endogenous pituitary
isoforms. The change in the ratio between serum
concentrations of 22K GH and other pituitary-derived
isoforms of GH (Figure 1) forms the basis of one
approach to testing for GH [30, 31].
The second current approach to a GH doping test is
based on the physiological effects of GH that result in
increased circulating concentrations of proteins that have
a longer half-life and a more stable serum concentration
than GH (Figure 1). GH stimulates production of
insulin-like growth factor-I (IGF-I), which mediates many
of the anabolic actions of GH, both by the liver, which is
the main source of circulating IGF-I, and in other
tissues where it has autocrine and paracrine effects. GH
also stimulates the hepatic production of IGF binding
protein-3 (IGFBP-3) and the acid labile subunit (ALS),
which together with IGF-I form the circulating ternary
complex [32, 33]. Therefore, in response to GH, the
serum concentrations of these IGF axis proteins increase.
GH also stimulates bone and connective tissue turnover
both directly and via IGF-I, resulting in increased
concentrations of specific collagen peptides related to
collagen synthesis and degradation [34]. These include the
marker of bone formation (N-terminal propeptide of type
I procollagen [PINP]), the marker of bone resorption
(C-terminal telopeptide of type I collagen [ICTP]) and
the marker of connective tissue synthesis (N-terminal
propeptide of type III procollagen [abbreviated as PIIINP
or PIIIP, referring to measurements by different assays])
[35]. The half-lives of the IGF axis proteins and
collagen markers, which range from 90 h to > 500 h [36],
are considerably longer than that of GH. The increases
in the serum concentrations of these GH-responsive
markers form the basis of the second approach to GH
testing [37].
5 GH isoform approach
Application of the GH isoform approach to doping
testing has been made possible by the development of
immunoassays that differentiate between the isoforms
of GH, in particular between 22K GH and other GH isoforms. The Strasburger group has developed a method
based on two immunoassays that distinguish between
recombinant 22K GH and all endogenous GH isoforms using specific monoclonal antibodies (MAbs) [30, 38].
One of the assays uses an MAb that preferentially
recognizes recombinant 22K GH (Rec-GH), and the second
assay uses an MAb that is permissive and recognizes all
pituitary isoforms (Pit-GH). Sandwich-type
immunoassays using a microtitre-plate format have been established
using these specific MAb as capture antibodies. The
ratio of the measurements from the Rec-GH and Pit-GH
assays (Rec : Pit ratio) indicates the relative abundance
of 22K GH. Because of the different affinities of the
antibodies for 22K GH and pituitary GH, the absolute
concentrations are measured differently by each assay.
This can result in ratios greater than 1.0, which indicate
a relatively higher proportion of 22K GH, rather than a
22K GH content greater than 100%, which is
theoretically impossible [30].
Following administration of recombinant 22K GH,
there is an increase in the relative abundance of 22K GH
compared to the other forms of GH, and the Rec : Pit
ratio is increased. Good separation of the Rec : Pit ratio
for GH-treated versus control samples (Rec : Pit ratio
GH: 1.43 ± 0.21 vs. control 0.50 ± 0.12, mean ± SD) has
been reported [38]. The window of opportunity for
detection is relatively short, possibly up to 24_36 h after
the last GH injection [30]. To meet the requirement of
WADA for a confirmatory test for any immunological
assay using a different antibody that recognizes a
different epitope of the peptide or protein being assayed, the
Strasburger group has further established another pair
of Rec and Pit assays using different specific MAbs [39].
An alternate isoform-based method for detection of
exogenous GH has been developed using measurement of the specific 20K GH isoform, together with
measurement of 22K GH. Specific MAbs to 20K GH have been
raised that do not cross-react with 22K GH and a
specific sandwich ELISA established for the measurement
of 20K GH in human serum [40, 41]. Co-secretion of
20K GH with 22K GH, with peaks of secretion
coinciding during the day, has been demonstrated, indicating
that under normal physiological conditions, the
circulating concentration of 20K is in a constant proportion to
22K GH [26, 41] (Figure 2). Administration of
exogenous GH, however, results in rapid reduction of 20K
GH concentration, due to negative feedback regulation
on pituitary secretion of 20K GH (Figure 2). Following
injection of exogenous 22K GH, the increase in
circulating 22K and the reduction in 20K GH result in a rapid
change in the ratio of 22K to 20 K GH for up to 24 h [26].
Current studies from our group on the changes in the
ratio following daily injections of 2 mg GH for 8 weeks
also suggest that the window of opportunity for
detection might be within 24 h of injection (unpublished results).
The ratio between 22K and 20K GH is relatively stable,
with little effect of age, gender, body weight or height in
the general population [41]. Using a study group of nearly
1 000 elite athletes from four major ethnic groups, our
group has shown that the effect of age, gender, body mass
index (BMI), ethnicity and sport type on the
22K/20K ratio is minimal [42]. The stability of the ratio to the effect
of demographic factors and sport type renders it a
promising measure of exogenous GH abuse. The effect of
exercise on the isoform approach to detection of GH has
been investigated in a study of male athletes, in which all
the molecular isoforms of GH measured increased with
acute exercise. The proportion of non-22K GH isoforms
increased after exercise due in part to the slower
disappearance rates of 20K and possibly other isoforms [43],
indicating that the effect of exercise would likely be false
negatives, rather than erroneous false positives. Supraphysiological doses of GH administered to male
athletes suppressed exercise-stimulated endogenous GH
isoforms, which also supports the use of the isoform
approach [31].
A major limitation of the isoform approach is the short
window of opportunity of detection of possibly 24_36 h
after injection, which limits its use primarily to
no-advance-notice out-of-competition testing. In addition, the
isoform approach can only detect 22K GH, and does not
detect administration of pituitary-derived GH, IGF-I or
GH secretagogues. The differential isoform method was
implemented by WADA for the 2004 (Athens) and 2006
(Turin) Olympic Games. To date, however, there have
been no irregular findings from sports samples tested
using this method, because of the short window of
opportunity for detection, which makes detection unlikely
during competition periods. More widespread
implementation of the method has been limited by the availability
of the assay materials. Commercial kits have now been
developed and it is anticipated that the differential isoform
approach will soon be implemented by many anti-doping
agencies and testing laboratories.
6 GH-responsive marker approach
The GH-responsive marker approach, based on detecting increased levels of GH-responsive proteins in
blood, has the advantage of a longer window of
opportunity for detection than the isoform-based approach. The
collaborative GH-2000 group pioneered the evaluation of
serum IGF axis makers: IGF-I, IGFBP-1, IGFBP-2, IGFBP-3 and ALS, and serum markers of bone and
connective tissue turnover: osteocalcin, bone-specific
alkaline phosphatase, C-terminal propeptide of type I
collagen (PICP), ICTP and PIIIP [44]. Parallel studies have
been performed to determine the effect of exercise on
these markers. Although acute exercise transiently
increased IGF-I, IGFBP-3 and ALS, the increases were
much smaller than those in response to GH
administration alone [45]. The same was true for osteocalcin, PICP,
ICTP and PIIIP, the responses of which were greater
and more prolonged following GH than after acute
exercise [46].
The effect of administration of GH for 4 weeks on
these GH-responsive markers was examined in a randomized double-blind placebo-controlled study in 99
young athletically trained men and women, using two
doses of GH: 0.033 mg/kg/day and 0.067 mg/kg/day.
The IGF axis proteins IGF-I, IGFBP-3 and ALS all
increased in response to GH, with the greatest response in
IGF-I. Men were significantly more responsive than
women. All IGF proteins had returned to baseline within
a few days of cessation of treatment, except for IGF-I,
which was elevated for longer in men [47]. All the
markers of bone and connective tissue turnover increased in
response to GH, with ICTP and PIIIP exhibiting the
greatest responses, and peak increments being greater in men
than in women. Osteocalcin, ICTP and PIIIP remained
significantly elevated for up to 8 weeks after cessation
of treatment, which clearly indicates the potential for a
longer window of opportunity for detection using these
markers [48]. Other placebo-controlled administration
studies have also shown the potential for IGF axis and
collagen peptides as markers of GH administration [49,
50]. A recent evaluation of IGFBP-4 and IGFBP-5
indicates that they will not be useful as IGF-I independent
markers [51]. In a double-blind placebo-controlled study
of GH administration to recreational athletes, our group
recently showed that the response to GH is greater in
men than in women for IGF-I, IGFBP-3, ALS and collagen markers, with the peak response being greater for
IGF-I and for PIIINP. The collagen markers remained
elevated for longer than the IGF axis markers, indicating
the potential for an extended window of detection using
the collagen peptides ICTP and PIIINP [52].
The application of this method based on
GH-responsive markers requires extensive normative data in elite
athletes to identify the factors influencing their levels in
blood and to establish normal reference ranges. In a
large cross-sectional study of IGF-I, IGFBP-3, ALS,
PINP, ICTP and PIIINP in over 1 000 elite athletes from
12 countries representing four major ethnic groups, we
reported that age and gender are the major determinants
of variability for IGF-I and the collagen peptides, whereas
ethnicity accounts for less than 6% of the attributable
variation, except for IGFBP-3 and ALS [53]. There is a
significant negative correlation between age and all these
GH-responsive markers, similar to the correlation seen
in the general population [54, 55] and age is the major
contributor to variability, especially for the collagen
peptides (Figure 3). There are significant differences
between men and women; however, the contribution of
gender is smaller than that of age, except for IGFBP-3
and ALS. The contributions of BMI and sport type are
both modest compared with those of age and gender (Figure 3). Therefore, our study of elite athletes in the
out-of-competition setting indicates that a test based on
IGF-I and the collagen markers must take age into
account for men and women, and that ethnicity is unlikely
to be a confounder for IGF-I and the collagen markers
[53]. Our findings on the influence of age, gender, BMI
and sport type have also been confirmed in a study of
mostly Caucasian elite athletes in the post-competition
setting [56], which also concludes that sport category is
not a significant predictor compared to age and gender.
The successful application of the markers approach
also requires data on the within-subject variability of the
IGF axis and collagen peptides over time. Examination
of short-term variability in our cohort of over 1 000 elite
athletes shows that the within-subject variability is less
for the collagen markers and for IGFBP-3 and ALS, than
for IGF-I (Nguyen TV et al., unpublished data).
Statistical modelling, such as the Bayesian approach, and use
of multiple measurements might, therefore, assist in the
application of the marker approach to doping tests.
Further data on longer-term within-subject variability, which
has been addressed by the GH-2000 group [44], is also
required. The effect of injury on the collagen peptides in
athletes also warrants investigation. Distinct changes in
serum biochemical bone markers, both in the early stages
after fracture and up to several weeks later, have been
described following lower limb fractures, as a result of
bone remodeling and collagen III synthesis in fracture
healing [57, 58]. Preliminary studies in subjects from
sport injury clinics have also been described by the
GH-2000 group [44], and larger studies are underway.
A robust test for GH must also take into account the
possible confounding effects of multiple
performance-enhancing substances that are used by athletes that
practice polypharmacy. We investigated the effect of
administration of recombinant human erythropoietin (r-HuEPO)
on GH-responsive markers in young male recreational
athletes and found no significant treatment effect
compared to baseline on IGF-I, IGFBP-3, ALS, PINP, ICTP
or PIIINP [59]. Therefore, use of r-HuEPO by athletes
should not affect the validity of a test using these IGF
axis and collagen markers. We have also recently
investigated the effect of testosterone on GH-responsive
markers in a double blind placebo-controlled study of
recreational athletes. Testosterone alone did not affect IGF-I,
IGFBP-3 or ALS and only modestly increased PINP, ICTP
and PIIINP. Combined administration of testosterone
with GH did not affect the sensitivity of the markers to
GH alone, except for PIIINP, where combined treatment
significantly increased the peak response to GH [52].
A GH doping test based on the GH-responsive
markers should not rely on a single marker, but use a
combination of markers. The different pharmacodynamic
profiles of the IGF axis and collagen markers have been
indicated particularly by studies with extended washout
periods, showing the prolonged elevation of collagen
markers after cessation of GH administration [47_49,
52]. This indicates the benefits of using a combination
of several markers to detect GH doping both during
active administration and during washout. Combinations
of IGF-I, IGFBP-3, PIIINP and ICTP have been proposed [37, 49, 50]. In our cross-sectional study, no
individuals had extreme values (outside the 99%
reference interval) both for IGF-I and for the collagen
markers in the same sample, which confirms that the use of
IGF-I and a collagen marker will increase the specificity
of the test [53]. Algorithms based on IGF-I and PIIINP
show promise in discriminating GH-treated from
placebo-treated subjects, with low false positive rates in
particular when sex-specific algorithms including age are used
to account for the effects of age and gender on these
markers [37, 49, 60]. Our recent GH administration
study highlights the potential of IGF-I, PIIINP and ICTP
in combination as promising discriminators of GH
administration against our reference population of elite
athletes, both during treatment and for up to several weeks
following treatment, because of the longer time course
of the collagen marker responses (Nelson AE et
al., unpublished results).
In summary, implementation of the GH-responsive
marker approach will clearly extend the window of
opportunity for the detection of GH. This method also has
the potential to detect abuse of other agents, such as
cadaveric pituitary GH, which is reportedly still a source of
illicit GH, although no longer used clinically because of
the risk of transmission of Creutzfeldt-Jakob disease,
recombinant placental GH, GH secretagogues and IGF-I.
Extensive data is now available that validates the use of
the GH-marker approach, although some additional data
is still required. The main hurdles to be overcome in the
implementation of the markers approach as a doping test
are technical and logistic issues, in particular those
relating to ensuring availability to testing laboratories of
standardized assays with assured supplies of antibodies.
7 Novel approaches to the detection of GH
Novel approaches are being investigated to identify
new markers or profiles of gene expression or proteins
that are diagnostic of GH use. One line of investigation
is the study of gene expression in peripheral blood
leucocytes, because leucocytes are the only source of
genetic material readily available from the current testing
substrates. There is strong evidence that GH regulates
various aspects of the immune system and that leucocytes
also respond directly both to GH and to IGF-I [61];
therefore, GH administration can be expected to result in
gene expression changes in leucocytes, potentially with
a long time course because of secondary effects such as
those via IGF-I. A pilot study has examined changes in
expression of selected genes in human haematopoietic
cells treated with GH using real time polymerase chain
reaction [62]. We are currently investigating gene
expression in peripheral blood leucocytes from subjects
following treatment with GH in vivo, to determine a
diagnostic gene expression "fingerprint". We are using
Affymetrix microarray gene profiling to examine
genome-wide gene expression of RNA extracted from leucocytes
[63]. The methodology established might also be useful
for detecting abnormal gene expression in response to
gene doping.
Proteomic methods are also being applied to serum
to investigate novel protein markers or diagnostic profiles.
Protein expression profiles have been studied in serum
using surface-enhanced laser desorption/ionization
time-of-flight mass spectrometry (SELDI-TOF MS), in which
proteins are bound to proprietary protein chips with
different adsorptive surfaces, then mass to charge ratios
determined following ionization of the bound proteins.
SELDI-TOF analysis has indicated differences in the
serum protein profiles from subjects treated with GH
compared to placebo and has identified haemoglobin
α-chain as a single biomarker classifier [64], thus demonstrating
the potential for this method for GH doping detection.
8 Conclusions and future directions
Robust tests for GH detection are required to
enforce bans on GH and to deter its use in sport. Two
current approaches to testing for GH based on
measurement of GH isoforms and on GH-responsive markers
have been extensively developed. These tests will likely
be used in a complementary manner, due to their
different windows of opportunity for detection characteristics.
WADA has implemented one method based on differential GH isoforms to a limited extent and with the
development of commercial assays, the test should soon be more
widely implemented. The GH-marker approach will
extend the window of opportunity for detection and can
detect other forms of GH and GH secretagogues. Its
implementation is dependent largely on establishing the
availability of standardized assays with assured supplies
of antibodies to testing laboratories.
Future directions for research might include the use
of other platforms for the measurement of the GH isoforms and GH-markers used in the current approaches.
New immunoassay platforms, including multiplexed
particle-based flow cytometric assays, such as the Luminex
system [65] represent technical advances that will
enhance efficiency and sensitivity. Mass spectrometry
methods may also be applied to quantification of GH
isoforms and of GH-responsive markers. Recently,
quantification of IGF-I and IGFBP-3 in human serum by
liquid chromatography-tandem mass spectrometry
(LC-MS/MS) using synthetic stable-isotope labeled peptides as
internal standards [66] and a mass-spectrometry-based
assay for rat PINP [67] have been described.
The use of an "athlete's passport" that documents
measurements of biological parameters over time has
been proposed both in the wider context of monitoring
the health of the athlete and to assist in the detection of
banned substances, as recently described for
erythropoietin [68]. It is proposed that to create the "passport",
the athlete would take a baseline test that would provide
reference levels for the individual. The "passport" would
enable detection of abnormal levels that differ to the
baseline for that athlete, rather than comparing the levels
to normative ranges alone. This has the potential to
increase the sensitivity of methods, particularly those based
on biomakers such as the GH-responsive marker approach.
In conclusion, robust tests should soon be in place
to detect GH and to enforce the ban on its abuse.
Commercial assays are now available that will enable wide
implementation of the isoform-based approach. The
GH-responsive marker approach will extend the window of
opportunity for detection of GH, and the technical hurdles
to its implementation are currently being addressed by
the anti-doping authorities. In addition to further
development of these two approaches, novel approaches must
continue to be pursued in order to expand the repertoire
of testing approaches available and to maintain deterrence
of GH doping.
Acknowledgment
Research by the authors has been supported by the
World Anti-Doping Agency and by the Australian
Government through the Anti-Doping Research Program of the
Department of Communications, Information
Technology and the Arts.
References
1 Bamberger M, Yaeger D. Over the edge: special report. Sports
Illustrated 1997; 86: 64.
2 Rickert VI, Pawlak-Morello C, Sheppard V, Jay MS. Human
growth hormone: a new substance of abuse among adolescents?
Clin Pediatr (Phila) 1992; 31: 723_6.
3 Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE.
Monitoring the Future national survey results on drug use,
1975_2006: Volume I, Secondary school students. Bethesda: NIH
Publication 2007.
4 National Collegiate Athletic Association. NCAA Study of
Substance Use of College Student-Athletes. 2006. Available from
URL:
http://www.ncaa.org/library/research/substance_use_habits/
2006/2006_substance_use_report.pdf
5 Saugy M, Robinson N, Saudan C, Baume N, Avois L, Mangin P.
Human growth hormone doping in sport. Br J Sports Med 2006;
40: i35_9.
6 Parkinson AB, Evans NA. Anabolic androgenic steroids: a survey
of 500 users. Med Sci Sports Exerc 2006; 38: 644_51.
7 Perry PJ, Lund BC, Deninger MJ, Kutscher EC, Schneider J.
Anabolic steroid use in weightlifters and bodybuilders: an internet
survey of drug utilization. Clin J Sport Med 2005; 15: 326_30.
8 Dean H. Does exogenous growth hormone improve athletic
performance? Clin J Sports Med 2002; 12: 250_3.
9 Rennie MJ. Claims for the anabolic effects of growth hormone:
a case of the emperor's new clothes? Br J Sports Med 2003; 37:
100_5.
10 Gibney J, Healy ML, Sonksen PH. The growth
hormone/insulin-like growth factor-I axis in exercise and sport. Endocr Rev 2007;
28: 603_24.
11 Healy ML, Gibney J, Russell-Jones DL, Pentecost C, Croos P,
Sonksen PH, et al. High dose growth hormone exerts an anabolic
effect at rest and during exercise in endurance-trained athletes. J
Clin Endocrinol Metab 2003; 88: 5221_6.
12 Deyssig R, Frisch H, Blum WF, Waldhor T. Effect of growth
hormone treatment on hormonal parameters, body composition
and strength in athletes. Acta Endocrinol (Copenh) 1993; 128:
313_8.
13 Berggren A, Ehrnborg C, Rosen T, Ellegard L, Bengtsson BA,
Caidahl K. Short-term administration of supraphysiological
recombinant human growth hormone (GH) does not increase
maximum endurance exercise capacity in healthy, active young men
and women with normal GH-insulin-like growth factor I axes. J
Clin Endocrinol Metab 2005; 90: 3268_73.
14 Nelson AE, Ho KK. Abuse of growth hormone by athletes. Nat
Clin Pract Endocrinol Metab 2007; 3: 198_9.
15 Johannsson G, Gibney J, Wolthers T, Leung KC, Ho KK.
Independent and combined effects of testosterone and growth
hormone on extracellular water in hypopituitary men. J Clin
Endocrinol Metab 2005; 90: 3989_94.
16 Karila TA, Karjalainen JE, Mantysaari MJ, Viitasalo MT, Seppala
TA. Anabolic androgenic steroids produce dose-dependant
increase in left ventricular mass in power atheletes, and this effect
is potentiated by concomitant use of growth hormone. Int J
Sports Med 2003; 24: 337_43.
17 Mark PB, Watkins S, Dargie HJ. Cardiomyopathy induced by
performance enhancing drugs in a competitive bodybuilder. Heart
2005; 91: 888.
18 Weissberger AJ, Ho KY, Stuart MC. Quantification of urinary
growth hormone (GH) excretion by centrifugal ultrafiltration
and radioimmunoassay: appraisal of the relationship between 24
h urinary GH and mean 24 h serum GH levels in normal and
abnormal states of GH secretion. Clin Endocrinol (Oxf) 1989;
30: 687_98.
19 Flanagan DE, Taylor MC, Parfitt V, Mardell R, Wood PJ,
Leatherdale BA. Urinary growth hormone following exercise to
assess growth hormone production in adults. Clin Endocrinol
(Oxf) 1997; 46: 425_9.
20 Saugy M, Cardis C, Schweizer C, Veuthey JL, Rivier L. Detection
of human growth hormone doping in urine: out of competition
tests are necessary. J Chromatogr B Biomed Appl 1996; 687:
201_11.
21 Kazlauskas R, Howe C, Trout G. Strategies for rhEPO detection
in sport. Clin J Sport Med 2002; 12: 229_35.
22 Holl RW, Schwarz U, Schauwecker P, Benz R, Veldhuis JD, Heinze
E. Diurnal variation in the elimination rate of human growth
hormone (GH): the half-life of serum GH is prolonged in the
evening, and affected by the source of the hormone, as well as by
body size and serum estradiol. J Clin Endocrinol Metab 1993; 77:
216_20.
23 Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation
of growth hormone secretion in experimental animals and the
human. Endocr Rev 1998; 19: 717_97.
24 Baumann G. Growth hormone heterogeneity in human pituitary
and plasma. Horm Res 1999; 51 Suppl 1: 2_6.
25 De Palo EF, De Filippis V, Gatti R, Spinella P. Growth hormone
isoforms and segments/fragments: molecular structure and
laboratory measurement. Clin Chim Acta 2006; 364: 67_76.
26 Leung KC, Howe C, Gui LY, Trout G, Veldhuis JD, Ho KK.
Physiological and pharmacological regulation of 20-kDa growth
hormone. Am J Physiol Endocrinol Metab 2002; 283: E836_43.
27 Zhan X, Giorgianni F, Desiderio DM. Proteomics analysis of
growth hormone isoforms in the human pituitary. Proteomics
2005; 5: 1228_41.
28 Lewis UJ, Sinha YN, Lewis GP. Structure and properties of
members of the hGH family: a review. Endocr J 2000; 47 Suppl:
S1_8.
29 Muller EE, Locatelli V, Cocchi D. Neuroendocrine control of
growth hormone secretion. Physiol Rev 1999; 79: 511_607.
30 Bidlingmaier M, Wu Z, Strasburger CJ. Test method: GH. Baillieres
Best Pract Res Clin Endocrinol Metab 2000; 14: 99_109.
31 Wallace JD, Cuneo RC, Bidlingmaier M, Lundberg PA, Carlsson
L, Boguszewski CL, et al. Changes in non-22-kilodalton (kDa)
isoforms of growth hormone (GH) after administration of
22-kDa recombinant human GH in trained adult males. J Clin
Endocrinol Metab 2001; 86: 1731_7.
32 Baxter RC. Insulin-like growth factor binding proteins in the
human circulation: a review. Horm Res 1994; 42: 140_4.
33 Jones JI, Clemmons DR. Insulin-like growth factors and their
binding proteins: biological actions. Endocr Rev 1995; 16: 3_34.
34 Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg
MC. Growth hormone and bone. Endocr Rev 1998; 19: 55_79.
35 Seibel MJ. Molecular markers of bone turnover: biochemical,
technical and analytical aspects. Osteoporos Int 2000; 11 Suppl
6: S18_29.
36 McHugh CM, Park RT, Sonksen PH, Holt RI. Challenges in
detecting the abuse of growth hormone in sport. Clin Chem
2005; 51: 1587_93.
37 Powrie JK, Bassett EE, Rosen T, Jorgensen JO, Napoli R, Sacca
L, et al. Detection of growth hormone abuse in sport. Growth
Horm IGF Res 2007; 17: 220_6.
38 Wu Z, Bidlingmaier M, Dall R, Strasburger CJ. Detection of
doping with human growth hormone. Lancet 1999; 353: 895.
39 Bidlingmaier M, Strasburger CJ. Technology Insight: detecting
growth hormone abuse in athletes. Nat Clin Pract Endocrinol
Metab 2007; 3: 769_77.
40 Hashimoto Y, Ikeda I, Ikeda M, Takahashi Y, Hosaka M, Uchida
H, et al. Construction of a specific and sensitive sandwich
enzyme immunoassay for 20 kDa human growth hormone. J
Immunol Methods 1998; 221: 77_85.
41 Tsushima T, Katoh Y, Miyachi Y, Chihara K, Teramoto A, Irie
M, et al. Serum concentration of 20K human growth hormone
(20K hGH) measured by a specific enzyme-linked immunosorbent
assay. Study Group of 20K hGH. J Clin Endocrinol Metab 1999;
84: 317_22.
42 Nelson AE, Ueki M, Nguyen TV, Leung KC, Howe CJ, Trout GJ,
et al. The influence of demographic factors on the ratio of
20-kDa and 22-kDa GH isoforms and the utility of the ratio for
detection of GH doping in sport. Growth Horm IGF Res 2006;
16 Supp B: S3.
43 Wallace JD, Cuneo RC, Bidlingmaier M, Lundberg PA, Carlsson
L, Boguszewski CL, et al. The response of molecular isoforms of
growth hormone to acute exercise in trained adult males. J Clin
Endocrinol Metab 2001; 86: 200_6.
44 Sonksen PH. Insulin, growth hormone and sport. J Endocrinol
2001; 170: 13_25.
45 Wallace JD, Cuneo RC, Baxter R, Orskov H, Keay N, Pentecost
C, et al. Responses of the growth hormone (GH) and insulin-like
growth factor axis to exercise, GH administration, and GH
withdrawal in trained adult males: a potential test for GH abuse in
sport. J Clin Endocrinol Metab 1999; 84: 3591_601.
46 Wallace JD, Cuneo RC, Lundberg PA, Rosen T, Jorgensen JO,
Longobardi S, et al. Responses of markers of bone and collagen
turnover to exercise, growth hormone (GH) administration, and
GH withdrawal in trained adult males. J Clin Endocrinol Metab
2000; 85: 124_33.
47 Dall R, Longobardi S, Ehrnborg C, Keay N, Rosen T, Jorgensen
JO, et al. The effect of four weeks of supraphysiological growth
hormone administration on the insulin-like growth factor axis in
women and men. GH-2000 Study Group. J Clin Endocrinol Metab
2000; 85: 4193_200.
48 Longobardi S, Keay N, Ehrnborg C, Cittadini A, Rosen T, Dall R,
et al. Growth hormone (GH) effects on bone and collagen
turnover in healthy adults and its potential as a marker of GH abuse
in sports: a double blind, placebo-controlled study. The GH-2000
Study Group. J Clin Endocrinol Metab 2000; 85: 1505_12.
49 Kniess A, Ziegler E, Kratzsch J, Thieme D, Muller RK. Potential
parameters for the detection of hGH doping. Anal Bioanal Chem
2003; 376: 696_700.
50 Sartorio A, Agosti F, Marazzi N, Maffiuletti NA, Cella SG,
Rigamonti AE, et al. Combined evaluation of resting IGF-I,
N-terminal propeptide of type III procollagen (PIIINP) and
C-terminal cross-linked telopeptide of type I collagen (ICTP)
levels might be useful for detecting inappropriate GH
administration in athletes: a preliminary report. Clin Endocrinol (Oxf)
2004; 61: 487_93.
51 Ehrnborg C, Ohlsson C, Mohan S, Bengtsson BA, Rosen T.
Increased serum concentration of IGFBP-4 and IGFBP-5 in healthy
adults during one month's treatment with supraphysiological doses
of growth hormone. Growth Horm IGF Res 2007; 17: 234_41.
52 Nelson AE, Meinhardt UJ, Walker IH, Hansen JL, Stone G, Seibel
MJ, et al. The influence of gender and testosterone on the
response to GH of IGF axis and collagen markers in young
recreational athletes: a double-blind placebo-controlled study. 89th
Meeting of the Endocrine Society, Toronto 2007: p1_539.
53 Nelson AE, Howe CJ, Nguyen TV, Leung KC, Trout GJ, Seibel
MJ, et al. Influence of demographic factors and sport type on
growth hormone_responsive markers in elite athletes. J Clin
Endocrinol Metab 2006; 91: 4424_32.
54 Juul A. Serum levels of insulin-like growth factor I and its binding
proteins in health and disease. Growth Horm IGF Res 2003; 13:
113_70.
55 Szulc P, Seeman E, Delmas PD. Biochemical measurements of
bone turnover in children and adolescents. Osteoporos Int 2000;
11: 281_94.
56 Healy ML, Dall R, Gibney J, Bassett E, Ehrnborg C, Pentecost C,
et al. Toward the development of a test for growth hormone
(GH) abuse: a study of extreme physiological ranges of
GH-dependent markers in 813 elite athletes in the postcompetition
setting. J Clin Endocrinol Metab 2005; 90: 641_9.
57 Kurdy NM, Bowles S, Marsh DR, Davies A, France M. Serology
of collagen types I and III in normal healing of tibial shaft
fractures. J Orthop Trauma 1998; 12: 122_6.
58 Stoffel K, Engler H, Kuster M, Riesen W. Changes in
biochemical markers after lower limb fractures. Clin Chem 2007; 53:
131_4.
59 Nelson AE, Howe CJ, Nguyen TV, Seibel MJ, Baxter RC,
Handelsman DJ, et al. Erythropoietin administration does not
influence the GH-IGF axis or makers of bone turnover in
recreational athletes. Clin Endocrinol (Oxf) 2005; 63: 305_9.
60 Erotokritou-Mulligan I, Bassett EE, Kniess A, Sonksen PH, Holt
RI. Validation of the growth hormone (GH)-dependent marker
method of detecting GH abuse in sport through the use of
independent data sets. Growth Horm IGF Res 2007; 17: 416_23.
61 Clark R. The somatogenic hormones and insulin-like growth
factor-1: stimulators of lymphopoiesis and immune function.
Endocr Rev 1997; 18: 157_79.
62 Paparini A, Impagnatiello F, Pistilli A, Rinaldi M, Gianfranceschi
G, Signori E, et al. Identification of candidate genes and
expression profiles, as doping biomarkers. Ann Ig 2007; 19:
303_14.
63 Lee CMY, Nelson AE, Lau AC, Kaplan W, Leung KC, Ho KK.
Microarray analysis of growth hormone responsive genes in
peripheral blood leucocytes in vivo. Endocr J 2006; 53 Suppl: 99.
64 Chung L, Clifford D, Buckley M, Baxter RC. Novel biomarkers
of human growth hormone action from serum proteomic
profiling using protein chip mass spectrometry. J Clin Endocrinol
Metab 2006; 91: 671_7.
65 Vignali DA. Multiplexed particle-based flow cytometric assays. J
Immunol Methods 2000; 243: 243_55.
66 Kirsch S, Widart J, Louette J, Focant JF, De Pauw E.
Development of an absolute quantification method targeting growth
hormone biomarkers using liquid chromatography coupled to
isotope dilution mass spectrometry. J Chromatogr A 2007; 1153:
300_6.
67 Han B, Copeland M, Geiser AG, Hale LV, Harvey A, Ma YL,
et al. Development of a highly sensitive, high-throughput, mass
spectrometry-based assay for rat procollagen type-I N-terminal
propeptide (PINP) to measure bone formation activity. J
Proteome Res 2007; 6: 4218_29.
68 Sharpe K, Ashenden MJ, Schumacher YO. A third generation
approach to detect erythropoietin abuse in athletes.
Haema-tologica 2006; 91: 356_63.